Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX-1431 in Adult Patients With Tourette Syndrome and Chronic Motor Tic Disorder
NCT03058562Phase 1Completed
- Sponsor
- Abide Therapeutics
- Start
- Feb 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABX-1431 in Tourette syndrome (TS) and chronic motor tic disorder (4 arms), sponsored by Abide Therapeutics. Primary endpoints: Modified Rush Video Scale at 8 hours, Yale Global Tic Severity Scale at 8 hours and 2 more. Started Feb 2017; status: completed.
02
Drugs
ABX-1431
03
Conditions
Tourette syndrome (TS)chronic motor tic disorder
Beyond the preview
Go deeper on NCT03058562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058562.